RHHBY has been the topic of a number of other reports. Credit Suisse Group dropped their price target on Roche from CHF 370 to CHF 350 and set a neutral rating on the stock in a research note on Thursday, May 19th. Cowen dropped their price target on Roche from $58.00 to $48.00 and set an outperform rating on the stock in a research note on Monday, June 27th. Morgan Stanley dropped their price target on Roche from CHF 370 to CHF 350 and set an equal weight rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price target on Roche from CHF 350 to CHF 325 and set a hold rating on the stock in a research note on Friday, July 22nd. Finally, Cowen dropped their price target on Roche from $58.00 to $48.00 and set an outperform rating on the stock in a research note on Monday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Hold and an average target price of $260.14.
Roche Stock Performance
Shares of Roche stock opened at $41.76 on Thursday. Roche has a one year low of $37.88 and a one year high of $53.86. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.73 and a current ratio of 0.93. The stock’s 50-day moving average is $41.55 and its 200 day moving average is $44.06.
Hedge Funds Weigh In On Roche
Roche Company Profile
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.